KINETIC study results
While a disappointment, this was not a large part of our valuation since treating hospitalised COVID-19 patients is a high bar where much of the pathological and immunological damage has already been done. The bulk of our fair value of Kinarus remains the use of KIN001 in wet age-related macular degeneration (wAMD).The discontinuation of the Phase 2 KINETIC study will result in some disappointment since it would have been a ‘quick win’. The bar was, however, very high and patients who have been admitted to hospital with COVID-19 have advanced disease where much of the inflammatory mediation that KIN001 was designed to reduce is already fulminant, requiring hospital support.
We are encouraged that the Phase 2 KINFAST study in ambulatory patients continues and have adjusted our valuation for this news: increasing the discount rate for KIN001 in the treatment of COVID-19 from 15% (which we apply to Kinarus’s other programs) to 30%, and modestly reducing FY2022 R&D spend.
These changes result in our fair valuation of Kinarus Therapeutics moving from CHF107.6m to CHF96.0m, equivalent to CHF 0.09 per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.